Senate Bill No. 253, introduced by Senator McMath, aims to regulate the use of peptides in Louisiana by establishing guidelines for healthcare providers and compounding pharmacies. The bill enacts R.S. 37:23.5, which prohibits professional or occupational licensing boards from restricting healthcare providers with prescriptive authority from prescribing peptides sourced from FDA-registered 503B outsourcing facilities or 503A compounding pharmacies, provided these entities comply with relevant federal regulations. Additionally, the bill mandates that prescribing providers ensure that any peptides prescribed are prepared according to these standards.

Furthermore, the bill allows Louisiana-licensed pharmacists in state-permitted pharmacies to compound and dispense peptides, as long as they adhere to the same federal compliance requirements. The proposed law is set to take effect on August 1, 2026, and includes amendments that extend its provisions to compounding pharmacies and update references to federal regulations applicable to prescribing providers and pharmacists.